Stockholders' Equity - Schedule of Outstanding and Exercisable Warrants (Details) - Warrant [Member] - USD ($) |
Dec. 31, 2024 |
Dec. 31, 2023 |
Jan. 01, 2023 |
|---|---|---|---|
| Schedule of Outstanding and Exercisable Warrants [Line Items] | |||
| Number of Warrants Outstanding, Balance | 10,074,195 | 10,074,195 | 10,074,195 |
| Weighted Average Exercise Price, Balance | $ 4.91 | $ 4.91 | $ 4.91 |
| Weighted Average Life (Years), Balance | 3 years | 4 years | 5 years |
| Aggregate Intrinsic Value, Balance |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. No definition available.
|
| X | ||||||||||
- Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|